Biotechnology News and Research RSS Feed - Biotechnology News and Research

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). [More]
OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

OBN, EMIG call on the UK government to allocate additional funding to support BMC programme

OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC). [More]
Low sexual desire among women can be treatable

Low sexual desire among women can be treatable

Low sexual desire is common among both pre- and post-menopausal women. It can cause personal distress, harm relationships, and have a negative impact on body image and self confidence. Yet few women seek medical care for this condition, and the reasons are explored in a timely article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. [More]
C3BS inks preferred access agreement with Mayo Clinic

C3BS inks preferred access agreement with Mayo Clinic

Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic. [More]
Early potty training linked to increased risk of developing daytime wetting problems later

Early potty training linked to increased risk of developing daytime wetting problems later

Children who start toilet training before age 2 have a three times higher risk of developing daytime wetting problems later, according to new research at Wake Forest Baptist Medical Center. [More]
Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Absorption Systems supports Pediatric Praziquantel Consortium led by Merck KGaA

Absorption Systems, a leader in preclinical contract testing of drugs, biologics, and medical devices, announces that it has been subcontracted by the German pharmaceutical company Merck KGaA to work on a new pediatric formulation of praziquantel. [More]
Cognizant announces acquisition of Cadient Group

Cognizant announces acquisition of Cadient Group

Cognizant today announced it has acquired Cadient Group, a full-service digital marketing agency that serves a broad spectrum of life sciences companies in the pharmaceutical, biotechnology, consumer health, and medical device industries. [More]
FDA designates NurOwn as Fast Track product for ALS treatment

FDA designates NurOwn as Fast Track product for ALS treatment

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). [More]
Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences. [More]
New method for extracting potential bone-producing cells from human fat

New method for extracting potential bone-producing cells from human fat

Within our fat lives a variety of cells with the potential to become bone, cartilage, or more fat if properly prompted. This makes adipose tissue, in theory, a readily available reservoir for regenerative therapies such as bone healing if doctors can get enough of those cells and compel them to produce bone. [More]
Novel test could revolutionise discovery of new prescription drugs

Novel test could revolutionise discovery of new prescription drugs

A new test developed by researchers from the University of Manchester could revolutionise the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available. [More]

BioCap conference showcased life sciences companies in the North

The unique BioCap conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry, was a great success, combining the forces of science and financial investment enabling businesses from all over the North to secure essential funding. [More]
Women survivors of sexual abuse may suffer emotional distress during pelvic examination

Women survivors of sexual abuse may suffer emotional distress during pelvic examination

Women who have a history of violent sexual abuse may suffer emotional distress during a routine pelvic examination. Healthcare providers would benefit from greater awareness of symptoms predictive of examination-related distress in this patient population, according to a study published in Violence and Gender, a new peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead therapeutic being developed for the treatment of sickle cell disease. [More]
Family physician  answers questions related to Ebola virus

Family physician answers questions related to Ebola virus

According to the Centers for Disease Control, the outbreak of Ebola in four West African countries is one of the largest outbreaks of the disease in history. [More]
Metamark expands prostate cancer test services to include PROGENSAPCA3 assay

Metamark expands prostate cancer test services to include PROGENSAPCA3 assay

Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. [More]

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Alimera Sciences, Inc. (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules). [More]
Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

DanDrit Biotech A/S ("DanDrit Denmark"), the subsidiary of DanDrit Biotech USA, Inc. ("DanDrit"), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino" - IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa. [More]
Allakos secures additional $10M investment to expand its development portfolio

Allakos secures additional $10M investment to expand its development portfolio

Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody. [More]
Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial. [More]